Kymera Therapeutics

KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo

Read more

Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases

Read more

Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Read more

STAT3 degraders inhibit Th17 development and cytokine production resulting in profound inhibition of collagen-induced autoimmune murine arthritis

Read more

STAT3 Degraders Inhibit Cellular Activation, Cytokine Production, and Th17 Development, Resulting in Profound Inhibition of Autoimmunity in the MOG-EAE Model of CNS Inflammation

Read more

The 63rd Annual ASH Meeting and Exposition, December 13, 2021

Read more

The 63rd Annual ASH Meeting and Exposition, December 11-14, 2021

Read more

SITC 2021, November 10-14, 2021

Read more

13th Annual T-Cell Lymphoma Forum, July 8-10, 2021

Read more

Ligase Targeting Drug Development Summit, May 25 – 27, 2021

Read more